Biotricity (OTC:BTCY) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.08) by 47.5 percent. This is a 740 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $3.988 million which missed the analyst consensus estimate of $4.100 million by 2.73 percent. This is a 8.05 percent increase over sales of $3.691 million the same period last year.